Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Adalimumab and Placebo in bDMARD-Naive Radiographic Axial Spondyloarthritis
jRCT2080223206Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (4 arms), sponsored by Eli Lilly and Company. Started May 2016; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on jRCT2080223206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223206.